What exactly is Biogen doing? When is a press release worth $12 billion? And what should patients make of whiplashing news?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. We’re devoting this entire episode to Biogen’s stunning announcement that aducanumab, its once-discarded treatment for Alzheimer’s disease, is getting a second life. First, we break down the news and its near-term implications. Then, STAT’s Sharon Begley joins us to dissect Biogen’s case and explain how outside experts have reacted. Later, we talk to a patient with Alzheimer’s who was in an aducanumab trial and is now dealing with the roller coaster of news. Finally, STAT’s Matthew Herper dials in to illustrate what’s going on behind the scenes at Biogen and what to watch for next.
For more on what we talk about, here’s the aducanumab news; here’s the reaction from scientists; here’s more on the patients in the trial; here’s how it’s playing on Wall Street; and here’s a profile of Biogen’s top scientist.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].
Having Alzheimer’s for a longer time does not help!
Comments are closed.